Gender differences in short-term effects of atorvastatin on lipid profile, fibrinolytic parameters, and endothelial function

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 18, Issue 3, 2008, Pages 182-188

  Sakabe, Koichi ^a   Fukuda, Nobuo ^a   Fukuda, Yamato ^a   Wakayama, Katsunori ^a   Nada, Teru ^a   Morishita, Satofumi ^a   Shinohara, Hisanori ^a   Tamura, Yoshiyuki ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Endothelial function; Fibrinolytic parameter; Gender; Lipid profile; Pleiotropic effects; Statin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PYRROLE DERIVATIVE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ARTICLE; BLOOD; BLOOD FLOW; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; MALE; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; REGIONAL BLOOD FLOW; SEX FACTORS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TREATMENT OUTCOME;

EID: 40649108340     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2006.10.008     Document Type: Article

References (32)

1. Marchesi S., Lupatteli G., Siepi D., Schillaci G., Vaudo G., Roscini A.R., et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 36 (2000) 617-621
2. Sasaki S., Kuwahara N., Kunitomo K., Harada S., Yamada T., Azuma A., et al. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 89 (2002) 386-389
3. Demir M., Acarturk E., Saamaz I., Cayli M., and Kikinc Y. Effects of atorvastatin on lipid profile and coagulation parameters. Curr Ther Res Clin Exp 62 (2001) 691-698
4. Stein D.T., Devaraj S., Balis D., Adams-Huet B., and Jialal I. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol 21 (2001) 2026-2031
5. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanchez-Pascuala R., Hernandez G., Diaz C., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 (1998) 2711-2719
6. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J., and Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial. Lancet 357 (2001) 577-581
7. Seljeflot I., Tonstad S., Hjermann I., and Arnesen H. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res 105 (2002) 285-290
8. Lopez S., Peiretti F., Bonardo B., Juhan-Vague I., and Nalbone G. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 152 (2000) 359-366
9. Sakabe K., Fukuda N., Wakayama K., Nada T., Shinohara H., and Tamura Y. Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients. Circ J 67 (2003) 866-870
10. Laufs U., Wassmann S., Hilgers S., Ribaudo N., Bohm M., and Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 88 (2001) 1306-1307
11. Gibson D.M., Bron N.J., Richens A., Hounslow N.J., Sedman A.J., and Whitfield L.R. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 36 (1996) 242-246
12. Ridker P.M., Rifai N., and Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103 (2001) 1191-1193
13. Allain C.C., Poon L.S., Chan C.S., Richmond W., and Fu P.C. Enzymatic determination of total serum cholesterol. Clin Chem 20 (1974) 470-475
14. Burstein M., and Scholnick H.R. Lipoprotein-polyanion-metal interactions. Adv Lipid Res 11 (1973) 67-108
15. Havel R.J., Eder H.A., and Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human plasma. J Clin Invest 34 (1955) 1346-1353
16. Nakajima K., Saito T., Tamura A., Suzuki M., Nakano T., Adachi M., et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 223 (1993) 53-71
17. Buege J.A., and Aust S.D. Microsomal lipid peroxidation. Methods Enzymol 52 (1987) 302-310
18. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39 (2002) 257-265
19. Tsunekawa T., Hayashi T., Kano H., Sumi D., Matsui-Hirai H., Thakur N.K., et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104 (2001) 376-379
20. Matsuda Y., Akita H., Terashima M., Shiga N., Kanazawa K., and Yokoyama M. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J 140 (2000) 753-759
21. Pedro-Botet J., Schaefer E.J., Bakker-Arkema R.G., Black D.M., Stein E.M., Corella D., et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 158 (2001) 183-193
22. Griffin B.A., Freeman D.J., Tait G.W., Thomson J., Caslake M.J., Packard C.J., et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 106 (1994) 241-253
23. Kamigaki A.S., Siscovick D.S., Schwartz S.M., Psaty B.M., Edwards K.L., Raghunathan T.E., et al. Low density lipoprotein particle size and risk of early-onset myocardial infarction in women. Am J Epidemiol 153 (2001) 939-945
24. Packard C.J., and Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 17 (1997) 3542-3556
25. Guerin M., Egger P., Le Goff W., Soudant C., Dupuis R., and Chapman M.J. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia. J Clin Endocrinol Metab 87 (2002) 4991-5000
26. Hirano T., Oi K., Sakai S., Kashiwazaki K., Adachi M., and Yoshino G. High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia. Atherosclerosis 141 (1998) 77-85
27. Nishi K., Uno M., Fukuzawa K., Horiguchi H., Shinno K., and Nagahiro S. Clinicopathological significance of lipid peroxidation in carotid plaques. Atherosclerosis 160 (2002) 289-296
28. Katalinic V., Modun D., Music I., and Boban M. Gender differences in antioxidant capacity of rat tissues determined by 2, 2′-azinobis (3-ethylbenzothiazoline 6-sulfonate; ABTS) and ferric reducing antioxidant power (FRAP) assays. Comp Biochem Physiol C Toxicol Pharmacol 140 (2005) 47-52
29. Cohn J.S., Marcoux C., and Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol 19 (1999) 2474-2486
30. Fukushima H., Kugiyama K., Sugiyama S., Honda O., Koide S., Nakamura S., et al. Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease. Am J Cardiol 88 (2001) 1370-1373
31. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., and van de Loo J.C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332 (1995) 635-641
32. John S., Delles C., Jacobi J., Schlaich M.P., Schneider M., Schmitz G., et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 37 (2001) 1351-1358